Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18506941 | 1.00 | ANPEP (0.64) | ANPEPLAP3 | |
| SCHEMBL18851740 | 0.85 | ANPEP (0.58) | ANPEPLAP3 | |
| SCHEMBL22103066 | 0.83 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL21190520 | 0.83 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL23969659 | 0.78 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL10592383 | 0.78 | ANPEP (1.00) | ANPEPLAP3 | |
| SCHEMBL16526079 | 0.78 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL12609422 | 0.78 | ANPEP (1.00) | ANPEPLAP3 | |
| SCHEMBL22667059 | 0.74 | ANPEP (0.50) | ANPEPLAP3 | |
| SCHEMBL20510145 | 0.74 | ANPEP (0.64) | ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ANPEP 4374/4885LAP3 2705/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | ANPEP 1693/4885LAP3 3177/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ANPEP 4374/4885LAP3 2705/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ANPEP 4374/4885LAP3 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.